4//SEC Filing
Riva Ridge Capital Management LP 4
Accession 0001214659-20-000278
CIK 0001586105other
Filed
Jan 9, 7:00 PM ET
Accepted
Jan 10, 4:21 PM ET
Size
13.4 KB
Accession
0001214659-20-000278
Insider Transaction Report
Form 4
Shim James
10% Owner
Transactions
- Sale
Common Stock, par value $0.001 per share
2019-12-23$2.50/sh−250,000$625,000→ 988,661 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2019-12-30$2.50/sh−50,000$125,000→ 938,661 total(indirect: See Footnotes)
Riva Ridge Capital Management LP
10% Owner
Transactions
- Sale
Common Stock, par value $0.001 per share
2019-12-30$2.50/sh−50,000$125,000→ 938,661 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2019-12-23$2.50/sh−250,000$625,000→ 988,661 total(indirect: See Footnotes)
RIVA RIDGE GP LLC
10% Owner
Transactions
- Sale
Common Stock, par value $0.001 per share
2019-12-23$2.50/sh−250,000$625,000→ 988,661 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2019-12-30$2.50/sh−50,000$125,000→ 938,661 total(indirect: See Footnotes)
Golden Stephen H
10% Owner
Transactions
- Sale
Common Stock, par value $0.001 per share
2019-12-23$2.50/sh−250,000$625,000→ 988,661 total(indirect: See Footnotes) - Sale
Common Stock, par value $0.001 per share
2019-12-30$2.50/sh−50,000$125,000→ 938,661 total(indirect: See Footnotes)
Footnotes (3)
- [F1]This Form 4 is being filed jointly by Riva Ridge Capital Management LP, a Delaware limited partnership ("RRCM"), Riva Ridge GP LLC, a Delaware limited liability company ("RRGP"), Stephen H. Golden ("Golden"), an individual, and James Shim ("Shim"), an individual (together, the "Reporting Persons"), with respect to certain securities of Zyla Life Sciences (f/k/a Egalet Corporation) (the "Issuer"). Neither the filing of this Form 4 nor any statements herein shall be deemed an admission that the Reporting Persons are members of a group, within the meaning of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), with respect to any equity securities of the Issuer.
- [F2]RRCM is the investment adviser to certain investment funds and accounts, including Riva Ridge Master Fund, Ltd., a Cayman Islands exempted company (the "Master Fund"). The securities reported in this row are held directly by the Master Fund.
- [F3]Each of RRCM, as the investment adviser to the Master Fund, and RRGP, as the general partner of RRCM, may be deemed a beneficial owner of the Issuer's securities held by the Master Fund. Each of Golden and Shim, as a managing member of RRGP with the power to exercise investment discretion, may be deemed a beneficial owner of the Issuer's securities held by the Master Fund. Each of the Reporting Persons disclaims beneficial ownership of any securities of the Issuer reported or referenced herein, for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of such Reporting Person's pecuniary interest, if any, therein.
Documents
Issuer
Zyla Life Sciences
CIK 0001586105
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001676700
Filing Metadata
- Form type
- 4
- Filed
- Jan 9, 7:00 PM ET
- Accepted
- Jan 10, 4:21 PM ET
- Size
- 13.4 KB